Are Reed Sternberg Cells B Cells? | What The Tests Reveal

Yes—most of these hallmark lymphoma cells start as germinal-center B cells, even if they stop acting like typical B cells.

Reed–Sternberg cells (often grouped with “Hodgkin and Reed–Sternberg” cells) are the defining malignant cells in classical Hodgkin lymphoma. Under the microscope they look oversized and odd. In real tissue they’re outnumbered by the normal immune cells around them. That mix—rare tumor cells, crowded bystander cells—can make the lineage question feel slippery.

So, are they B cells? In most patients with classical Hodgkin lymphoma, yes in origin: the malignant clone traces back to a B cell from the germinal center. What throws people off is that these cells often lose the usual B-cell surface markers and the gene program that makes a B cell “read” like one on a standard lab panel.

This article breaks down what “B-cell origin” means, which tests carry the most weight, why the cells can look like they’re from nowhere, and what parts of the pathology report are worth understanding if you’re a patient or caregiver.

What A “B Cell” Answer Means In A Pathology Report

When clinicians say “B-cell origin,” they mean lineage, not personality. Lineage is the cell’s ancestry. Personality is what the malignant cell expresses today—its proteins, signals, and behavior in tissue.

Reed–Sternberg cells can have a B-cell lineage while showing a mixed or muted marker pattern. That’s one reason Hodgkin lymphoma sits in its own bucket: it doesn’t behave like a typical B-cell lymphoma on a basic set of stains.

Think of it like tracing a family name even after someone changes their wardrobe, haircut, and habits. The DNA-level “family name” is still there, even when the surface look has shifted.

Are Reed Sternberg Cells B Cells? Evidence From Modern Testing

Multiple lines of lab work point to a B-cell start point in most classical Hodgkin lymphoma cases. The strongest clues come from DNA-level studies of immunoglobulin genes—genes B cells rearrange as they build an antibody repertoire. When a malignant population carries the same rearranged immunoglobulin pattern across many single cells, it tells you the tumor arose from one B-cell clone.

Large reviews sum up this picture: Hodgkin and Reed–Sternberg cells usually carry clonally rearranged immunoglobulin genes with somatic mutations that fit a germinal-center history, even when classic B-cell proteins are missing on the cell surface. A clear walkthrough of that molecular story appears in Haematologica’s review of classical Hodgkin lymphoma pathogenesis.

Gene-expression work lands in the same place. One widely cited analysis compared Reed–Sternberg cell transcripts with germinal-center B cells and found a B-cell lineage signal despite the cells’ unusual phenotype, reported in Blood’s Reed–Sternberg cell gene-expression study.

Why They Don’t Look Like Typical B Cells On Stains

A normal B cell carries a recognizable set of markers (CD20, CD79a, strong PAX5, surface immunoglobulin). Reed–Sternberg cells often show weak or missing versions of these. At the same time, they often show activation markers like CD30, plus other proteins that can muddy the first impression.

This “B-cell in disguise” pattern isn’t a footnote. It’s part of what makes the diagnosis specific. It also explains why pathologists rely on a combined read of morphology, immunostains, and the architecture of the lymph node rather than leaning on one marker.

The Rare Exception: Non-B Lineage Cases

Most classical Hodgkin lymphoma is B-cell–derived. Still, rare cases show evidence of a different origin, including T-cell lineage in a small subset described in research literature. For most patients, that rarity matters as a reminder that a single test result should never carry the whole diagnosis by itself.

Fast Primer On Reed–Sternberg Cells In Plain Language

Reed–Sternberg cells are large malignant lymphoid cells with distinctive nuclei. A basic definition from the National Cancer Institute notes that they’re abnormal lymphocytes seen in Hodgkin lymphoma and may contain more than one nucleus, which matches what pathologists see on biopsy slides. The NCI definition is here: NCI’s Hodgkin and Reed–Sternberg cell entry.

A patient-friendly overview that also states their B-cell origin is the Cleveland Clinic article on Reed–Sternberg cells. It’s written in everyday language, yet it matches the mainstream medical view: these tumor cells usually trace back to B cells.

One more nuance: “Reed–Sternberg cell” usually refers to classical Hodgkin lymphoma. There’s a related type called nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) where the malignant cells (often called LP or “popcorn” cells) more clearly show B-cell markers. People sometimes mix these up, so it helps to keep the subtype name in mind when reading any summary online.

How Scientists Track B-Cell Origin When Markers Fade

If you’ve ever wondered how anyone can claim lineage when a cell has dropped many lineage markers, the answer is molecular fingerprinting. Researchers use features that are hard to fake and hard to erase completely.

Immunoglobulin Gene Rearrangements

B cells rearrange immunoglobulin (Ig) genes as part of normal antibody development. That rearrangement pattern becomes a durable signature. When Reed–Sternberg cells from one patient share the same clonal Ig rearrangement, it points back to a single B cell as the ancestor.

This is a big deal because immunostains can be messy. DNA signatures are less subjective. If the clonal Ig rearrangement is present in the malignant cells, lineage isn’t a guess—it’s anchored in the way B cells are built.

Somatic Hypermutation Patterns

Germinal-center B cells introduce mutations into Ig genes as they refine antibody affinity. Reed–Sternberg cells often carry Ig genes with mutation patterns that fit that germinal-center step. That’s a second layer of “this used to be a germinal-center B cell,” separate from surface-marker loss.

Transcription Programs That Go Quiet

Even with B-cell DNA fingerprints, many Reed–Sternberg cells shut down the usual B-cell gene program. That helps explain weak PAX5 and missing surface immunoglobulin. It also hints at why these cells behave differently from most B-cell lymphomas.

Clinically, that “program shift” helps explain why a pathologist can say “B-cell lineage” while the stain list doesn’t look like a standard B-cell lymphoma worksheet.

What Pathologists Check On A Real Biopsy

In a real case, the question is less “Is it a B cell?” and more “Is this classical Hodgkin lymphoma, and is there a close mimic?” The work-up uses a panel of stains, sometimes molecular testing, then merges that with the pattern in the lymph node and the patient’s clinical picture.

Here’s a practical cheat sheet of signals that often show up when sorting lineage and diagnosis. It’s a simplification, not a replacement for a pathology report.

Clue	What You Often See In Classical Hodgkin Lymphoma	What This Points To
CD30	Positive in tumor cells	Fits a classic activation-marker pattern for this disease
CD15	Often positive	Helps separate classical Hodgkin lymphoma from some mimics
PAX5	Weak nuclear positivity	Hints at B-cell lineage even when other B markers are missing
CD20 / CD79a	Often negative or weak	Shows loss of typical B-cell surface phenotype
CD45	Usually negative in tumor cells	Helps separate from many non-Hodgkin lymphomas
Immunoglobulin gene clonality	Clonal rearrangement in most cases	Strong lineage anchor for a B-cell ancestor
EBV status (EBER)	Variable by subtype and region	Can add context in some cases and subtypes
Background cell mix	Many reactive immune cells, few tumor cells	Classic tissue pattern seen on biopsy

Why The Nearby Immune Cells Matter In Hodgkin Lymphoma

One odd feature of Hodgkin lymphoma is that the malignant cells can be scarce, yet the lymph node can look packed. Reed–Sternberg cells release signals that pull in T cells, macrophages, and other immune cells. Those bystanders can shape symptoms and even lab findings.

This also affects testing. If a biopsy sample contains few malignant cells, some assays can look “quiet” at first glance. Pathologists handle this by using multiple tissue sections, selecting stains with high yield in Hodgkin lymphoma, and ordering molecular tests only when they add clarity.

That’s also why the biopsy type matters. A larger core biopsy or excisional biopsy can give a cleaner architectural view than a small needle sample, which can miss the overall pattern.

What This Means For Patients And Families

If you’re reading this after a diagnosis, lineage can feel abstract. Here are the practical takeaways that usually help people make sense of the report and the next steps.

Diagnosis Comes From A Pattern, Not One Lab Result

Because tumor cells can lose B-cell markers, a “negative CD20” result does not rule out a B-cell lineage in this disease. Pathologists weigh morphology, CD30 and CD15 patterns, PAX5 intensity, and the architecture of the node, then add EBV testing or clonality testing when it adds resolution.

Treatment Choices Track Subtype And Stage

Therapy decisions in Hodgkin lymphoma are driven by subtype, stage, risk features, and response on imaging. The lineage label isn’t the steering wheel. What often matters more is what the tumor cells express now, since some therapies target current proteins on the malignant cells, like CD30.

If you see CD30 in your report, that isn’t just a stain result. It can connect directly to targeted treatments in certain settings. On the flip side, a weak B-cell marker pattern is common in classical Hodgkin lymphoma and doesn’t mean the diagnosis is shaky by itself.

When A Second Pathology Review Can Help

If results feel mixed—unclear markers, limited tissue, or a report that lists multiple possibilities—a hematopathology review can be a smart move. A second read often adds targeted stains or requests more tissue, which can clear up gray areas.

Common Look-Alikes And Why They Can Confuse The Picture

Several conditions can resemble classical Hodgkin lymphoma. The goal isn’t to memorize every mimic. It’s to see why the work-up is built as a cross-check system.

• Anaplastic large cell lymphoma: Can be CD30-positive with large atypical cells, so extra markers and the tissue pattern help separate it.
• Some large B-cell lymphomas: Certain variants can look “Hodgkin-like,” so CD45, B-cell marker strength, and molecular studies can sort the lineage.
• Reactive lymph node changes: Activated cells can show CD30 staining, so architecture and the full panel help avoid a false call.

Table Of Tests And Questions That Help You Read Your Report

Patients often want a short list of “what was checked” and “what does it mean.” The table below is built for that conversation. It won’t match every case, yet it can help you follow the logic in your results.

Test Or Finding	Question To Ask	What The Answer Can Tell You
CD30 / CD15 staining	Were tumor cells clearly positive?	Lines up with classical Hodgkin lymphoma when paired with morphology
PAX5 intensity	Was PAX5 weak, strong, or absent?	Weak positivity often fits B-cell lineage with altered phenotype
CD20 and other B markers	Were any B markers retained?	Retention varies; absence alone doesn’t erase B-cell ancestry
EBER (EBV) testing	Was EBV detected in tumor cells?	Can add subtype context in some cases
Flow cytometry limits	Was flow helpful or limited by low tumor cells?	Explains why some assays may read near-normal despite lymphoma
Molecular clonality	Was Ig gene clonality tested or needed?	Can anchor lineage when stains are ambiguous

Practical Takeaway For The B-Cell Question

If you want one clean sentence to carry with you: in most classical Hodgkin lymphoma, the malignant Reed–Sternberg clone traces back to a germinal-center B cell, even when standard B-cell markers fade. That blend—B-cell DNA fingerprints with an altered surface phenotype—is part of what makes this disease its own category in pathology and clinical care.

If your report uses terms like “HRS cells,” “CD30-positive,” “PAX5 weak,” or “classical Hodgkin lymphoma,” you’re seeing the same theme: lineage can be B cell, while the day-to-day marker pattern looks unusual. That’s normal for this diagnosis.